Status:
COMPLETED
Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Hyperinsulinism
Hypoglycemia
Eligibility:
All Genders
18-90 years
Brief Summary
The purpose of this study is to determine whether the investigators' new imaging modality (111In-exendin-4) has advantages in detecting insulinomas in comparison to conventional imaging.
Detailed Description
Insulinomas arise from pancreatic cells and are the most frequent hormone-active tumours of the pancreas. Insulinomas produce insulin and can become life threatening if they cannot be localised and re...
Eligibility Criteria
Inclusion
- Biochemically proven endogenous hyperinsulinism confirmed by hypoglycaemia with neuroglycopenic symptoms, inadequately high serum insulin and C-peptide concentrations and negative sulfonylurea screening as well as low serum beta-hydroxybutyrate concentrations
- Able and willing to provide written informed consent
Exclusion
- Renal insufficiency (creatinine \> 140 micromol/l)
- Pregnancy or positive pregnancy test which will be performed in all patients without contraception and aged \< 50 years
- Allergy to exendin-4 (Byetta®)
Key Trial Info
Start Date :
November 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00937079
Start Date
November 1 2007
End Date
December 1 2011
Last Update
January 9 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel, Institute of Nuclear Medicine
Basel, Canton of Basel-City, Switzerland, CH-4031